**REFERENCES**

[1] D. Quinn and R. Day, “Drug interactions of clinical importance,”

*Drug safety*, vol. 12, no. 6, pp. 393–452, 1995.

[2] T. Prueksaritanont, X. Chu, C. Gibson, D. Cui, K. L. Yee, J. Ballard,

T. Cabalu, and J. Hochman, “Drug–drug interaction studies: Regulatory

guidance and an industry perspective,” *The AAPS journal*,

vol. 15, no. 3, pp. 629–645, 2013.

[3] H. Kusuhara, “How far should we go? perspective of drug-drug

interaction studies in drug development,” *Drug metabolism and*

*pharmacokinetics*, vol. 29, no. 3, pp. 227–228, 2014.

[4] N. R. Crowther, A. M. Holbrook, R. Kenwright, and M. Kenwright,

“Drug interactions among commonly used medications. chart

simplifies data from critical literature review.” *Canadian Family*

*Physician*, vol. 43, p. 1972, 1997. [5] R. Nahta, M.-C. Hung, and F. J. Esteva, “The her-2-targeting

antibodies trastuzumab and pertuzumab synergistically inhibit

the survival of breast cancer cells,” *Cancer research*, vol. 64, no. 7,

pp. 2343–2346, 2004.

[6] T.-C. Chou, “Drug combination studies and their synergy quantification

using the chou-talalay method,” *Cancer research*, vol. 70,

no. 2, pp. 440–446, 2010.

[7] K. Venkatakrishnan, L. L. von Moltke, R. Obach, and D. J. Greenblatt,

“Drug metabolism and drug interactions: application and

clinical value of in vitro models,” *Current drug metabolism*, vol. 4,

no. 5, pp. 423–459, 2003.

[8] P. J. Neuvonen, M. Niemi, and J. T. Backman, “Drug interactions

with lipid-lowering drugs: mechanisms and clinical relevance,”

*Clinical Pharmacology & Therapeutics*, vol. 80, no. 6, pp. 565–581,

2006.

[9] Y. B¨ ottiger, K. Laine, M. L. Andersson, T. Korhonen, B. Molin, M.-

L. Ovesj¨ o, T. Tirkkonen, A. Rane, L. L. Gustafsson, and B. Eiermann,

“Sfinxła drug-drug interaction database designed for clinical decision

support systems,” *European journal of clinical pharmacology*,

vol. 65, no. 6, pp. 627–633, 2009.

[10] M. P. Pai, D. M. Graci, and G. W. Amsden, “Macrolide drug

interactions: an update,” *Annals of Pharmacotherapy*, vol. 34, no. 4,

pp. 495–513, 2000.

[11] J. Kuhlmann andW.M¨ uck, “Clinical-pharmacological strategies to

assess drug interaction potential during drug development,” *Drug*

*safety*, vol. 24, no. 10, pp. 715–725, 2001.

[12] S. Preskorn and S. Werder, “Detrimental antidepressant drug–

drug interactions: Are they clinically relevant?” *Neuropsychopharmacology*,

vol. 31, no. 8, pp. 1605–1612, 2006.

[13] D. Sridhar, S. Fakhraei, and L. Getoor, “A probabilistic approach

for collective similarity-based drug–drug interaction prediction,”

*Bioinformatics*, vol. 32, no. 20, pp. 3175–3182, 2016.

[14] S. Ekins and S. A.Wrighton, “Application of in silico approaches to

predicting drug–drug interactions,” *Journal of pharmacological and*

*toxicological methods*, vol. 45, no. 1, pp. 65–69, 2001.

[15] G. Jin, H. Zhao, X. Zhou, and S. T. Wong, “An enhanced petri-net

model to predict synergistic effects of pairwise drug combinations

from gene microarray data,” *Bioinformatics*, vol. 27, no. 13, pp.

i310–i316, 2011.

[16] R. Ferdousi, R. Safdari, and Y. Omidi, “Computational prediction

of drug-drug interactions based on drugs functional similarities,”

*Journal of Biomedical Informatics*, vol. 70, pp. 54–64, 2017.

[17] R. Safdari, R. Ferdousi, K. Aziziheris, S. R. Niakan-Kalhori, and

Y. Omidi, “Computerized techniques pave the way for drug-drug

interaction prediction and interpretation,” *BioImpacts: BI*, vol. 6,

no. 2, p. 71, 2016.

[18] N. P. Tatonetti, G. H. Fernald, and R. B. Altman, “A novel signal

detection algorithm for identifying hidden drug-drug interactionsin adverse event reports,” *Journal of the American Medical Informatics*

*Association*, vol. 19, no. 1, pp. 79–85, 2011.

[19] A. Gottlieb, G. Y. Stein, Y. Oron, E. Ruppin, and R. Sharan, “Indi: a

computational framework for inferring drug interactions and their

associated recommendations,” *Molecular systems biology*, vol. 8,

no. 1, p. 592, 2012.

[20] S. Yamazaki, T. R. Johnson, and B. J. Smith, “Prediction of drugdrug

interactions with crizotinib as the cyp3a substrate using a

physiologically based pharmacokinetic model,” *Drug Metabolism*

*and Disposition*, vol. 43, no. 10, pp. 1417–1429, 2015.

[21] L. Tari, S. Anwar, S. Liang, J. Cai, and C. Baral, “Discovering drug–

drug interactions: a text-mining and reasoning approach based on

properties of drug metabolism,” *Bioinformatics*, vol. 26, no. 18, pp.

i547–i553, 2010.

[22] S. Vilar, R. Harpaz, E. Uriarte, L. Santana, R. Rabadan, and

C. Friedman, “Drugłdrug interaction through molecular structure

similarity analysis,” *Journal of the American Medical Informatics*

*Association*, vol. 19, no. 6, pp. 1066–1074, 2012.

[23] S. Vilar, E. Uriarte, L. Santana, T. Lorberbaum, G. Hripcsak,

C. Friedman, and N. P. Tatonetti, “Similarity-based modeling in

large-scale prediction of drug-drug interactions,” *Nature protocols*,

vol. 9, no. 9, pp. 2147–2163, 2014.

[24] F. Cheng and Z. Zhao, “Machine learning-based prediction of

drug–drug interactions by integrating drug phenotypic, therapeutic,

chemical, and genomic properties,” *Journal of the American*

*Medical Informatics Association*, vol. 21, no. e2, pp. e278–e286, 2014.

[25] P. Li, C. Huang, Y. Fu, J. Wang, Z. Wu, J. Ru, C. Zheng, Z. Guo,

X. Chen, W. Zhou *et al.*, “Large-scale exploration and analysis of

drug combinations,” *Bioinformatics*, vol. 31, no. 12, pp. 2007–2016,

2015.